Table 3 Comparison of the blood flow-glucose metabolism parameters in patients with Estrogen Receptor /Progesterone Receptor/ c-erbB2 negative-positive, Triple negative-Non-triple negative and Ki67 1+ and 2+ breast cancer

TV

median (IR)

T-SUVmax

median (IR)

TACm

median (IR)

NG-SUVmax

median (IR)

NGACm

median (IR)

iLN-SUVmax

median (IR)

iLNACm

median (IR)

ER

+

5,76 (7,72)

7,7 (9,7)

9932 (9559)

1,5 (0,55)

1632 (1423)

3,7 (6,9)

4210 (9311)

–

9,84 (24,12)

6,5 (6,85)

14,960 (15257)

1,4 (0,73)

1474 (2014)

5,6 (15,55)

5883 (21220)

p

0,044*

> 0,05

0,041*

> 0,05

> 0,05

> 0,05

> 0,05

PR

+

4,80 (6,75)

5,9 (6,9)

8932 (9708)

1,5 (0,55)

1520 (1358)

3,7 (6,35)

4210 (5828)

–

8,88 (1783)

7,2 (7,5)

13,033 (14223)

1,4 (0,78)

1475 (1883)

4,7 (12,0)

5856 (18383)

p

0,019*

> 0,05

> 0,05

0,043*

> 0,05

> 0,05

> 0,05

c-erbB2

+

6,96 (17,96)

6,8 (7,93)

10,547 (8806)

1,6 (0,68)

1709 (1547)

3,95 (12,93)

5671 (20145)

–

6,44 (7,46)

6,85 (7,13)

12,030 (9323)

1,5 (0,6)

1475 (1743)

3,6 (7,38)

3770 (9865)

p

> 0,05

> 0,05

> 0,05

> 0,05

> 0,05

> 0,05

> 0,05

Tr

TrN

12,8 (41,34)

9,8 (14,4)

20,629 (12580)

1,0 (0,75)

1475 (1818)

5,15 (10,4)

5637 (17207)

nTrN

6,24 (7,86)

6,45 (6,73)

10,137 (8944)

1,5 (0,50)

1576 (1700)

3,7 (7,98)

4422 (11021)

p

> 0,05

> 0,05

0,011*

> 0,05

> 0,05

> 0,05

> 0,05

Ki-67

1+

6,08 (7,36)

6,1 (5,7)

11,998 (10098)

1,7 (0,7)

1431 (1748)

2,4 (2,4)

2608 (3832)

2+

6,64 (12,4)

6,9 (7,4)

10,752 (9336)

1,5 (0,70)

1520 (1837)

5,6 (10,4)

5485 (16927)

p

> 0,05

> 0,05

> 0,05

> 0,05

> 0,05

0,02*

> 0,05

Histologic grade

low

6.08 (10.74)

5.70 (5,13)

112,030 (9608)

1.50 (0.70)

2061 (1631)

3.60 (9.50)

4422 (14145)

high

6.52 (8.06)

8,95 (7,15)

12,450 (10716)

1.50 (0.65)

1181 (1376)

4.20 (8.33)

5252 (8887)

p

> 0,05

0.048*

> 0,05

> 0,05

0,003*

> 0,05

> 0,05